---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-040417"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T16:37:27.441928+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ProKidney posts FY2024 net loss of $163.3M; FDA confirms accelerated approval path for rilparencel

## Summary
- Net loss before noncontrolling interest $163.3M in 2024 vs $135.4M in 2023; R&D expenses rose 20% to $127.7M.
- Cash and equivalents $358.3M at year-end; secured $140M equity to fund operations into mid-2027.
- FDA confirmed accelerated approval pathway for rilparencel using eGFR slope as potential surrogate endpoint; PROACT 2 discontinued.
- Full Phase 2 REGEN-007 Group 1 data expected Q2 2025; interim June 2024 showed 18-month kidney function stabilization.
- Phase 3 PROACT 1 single study may support BLA; additional FDA meeting details expected mid-2025.

## SEC filing metadata
- accession: 0000950170-25-040417
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000095017025040417/0000950170-25-040417-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000095017025040417/prok-20250317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-040417
- JSON: https://secwatch.observer/filing/0000950170-25-040417.json
- Plain text: https://secwatch.observer/filing/0000950170-25-040417.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.